Adrenal insufficiency

Phase III LINC 3 Study Demonstrates That ISTURISA® (osilodrostat) Improves Physical Features Associated With Hypercortisolism in Patients With Cushing’s Disease

Retrieved on: 
Friday, May 13, 2022
Health, Pharmaceutical, Abdominal pain, Hypokalemia, Lactation, Infection, Magnesium, Hypotension, Mortality, Androgen, Plasma, Osilodrostat, Manchester, Week, Risk, American Association, Headache, Pituitary adenoma, Fatigue, Edema, Medical Affairs Bureau, Serum, Nausea, Cushing's disease, AACE, Arrhythmia, Incidence, Symptoms of COVID-19, Hirsutism, Hypoglycemia, The Lancet, Phase, Quality of life, Nature, Degenerative disease, Research, ACTH, III, Vomiting, Advertising, QT interval, ECG, Dizziness, Adrenal insufficiency, Waist, Uncertainty, Health, Association, Half-life, CYP3A4, Adult, FDA, Hyperandrogenism, Awareness, De novo, CYP2B6, Disease, QT, Microdeletion syndrome, Safety, LINC, Diagnosis, Hypertension, Pharmaceutical industry, Medical imaging, Birth control, Patient

Recordati Rare Diseases Inc. announced today that the Phase III LINC 3 study demonstrates ISTURISA (osilodrostat) improves physical features associated with hypercortisolism in patients with Cushings disease.

Key Points: 
  • Recordati Rare Diseases Inc. announced today that the Phase III LINC 3 study demonstrates ISTURISA (osilodrostat) improves physical features associated with hypercortisolism in patients with Cushings disease.
  • Patients with Cushings disease experience multiple physical manifestations of hypercortisolism that may reduce quality of life.
  • According to the abstract entitled Osilodrostat Therapy Improves Physical Features Associated with Hypercortisolism in Patients with Cushings Disease: Findings from the Phase III LINC 3 Study, 137 adult Cushings disease patients with mUFC >1.5 x the upper limit of normal were enrolled in the 48-week core phase to evaluate the safety and efficacy of ISTURISA in patients with Cushings disease.
  • Changes to physical features caused by Cushings disease can have a significant impact on patient health and well-being.

Neovasc Announces First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 12, 2022
Physician, Company, International, Adrenal insufficiency, Tiara, Indian stock exchange, Nasdaq, Webcast, Patient, NASDAQ, COVID-19, TSX, PMA, Prejudice, Conference, Interest, Compliance, Safety, GLOBE, Dismissal, Appeal, Video game, Pharmaceutical industry, Health insurance, Online gambling, Piping and plumbing fitting

VANCOUVER and MINNEAPOLIS, MN, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today reported financial results for the quarter ended March 31, 2022.

Key Points: 
  • VANCOUVER and MINNEAPOLIS, MN, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today reported financial results for the quarter ended March 31, 2022.
  • Achieved Q1 revenue of approximately $611,000, an increase of 35% over the same period in 2021, delivering a record first quarter.
  • Announced multiple third-party publications supporting safety, efficacy, and cost savings related to use of the Reducer to treat refractory angina.
  • Neovasc will be hosting a conference call and audio webcast today at 4:30 pm ET to discuss these results.

Recordati Rare Diseases Announces Multiple Scientific Abstracts to Be Highlighted at American Association of Clinical Endocrinology

Retrieved on: 
Tuesday, May 10, 2022
Health, Infectious Diseases, Other Science, Research, Science, Pharmaceutical, Biotechnology, Vomiting, PDT, Arrhythmia, Hypoglycemia, Edema, AACE, ACTH, Headache, Mortality, Androgen, Adrenocorticotropic hormone, Fatigue, Dizziness, Pituitary adenoma, Nature, CYP2B6, QT, Plasma, Barrow Neurological Institute, Quality of life, Symptoms of COVID-19, Hypotension, Patient, Infection, Hyperandrogenism, Abdominal pain, Half-life, Risk, Association, Degenerative disease, FDA, American Association, Diagnosis, Incidence, Advertising, Adrenal insufficiency, Magnesium, Adult, CYP3A4, Medical Affairs Bureau, Uncertainty, Hypokalemia, ECG, Lactation, QT interval, Serum, Research, Awareness, Hypertension, Nausea, Disease, Pharmaceutical industry, Birth control

Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be featured onsite at the American Association of Clinical Endocrinology (AACE) annual meeting being held in San Diego, California from May 12 14, 2022.

Key Points: 
  • Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be featured onsite at the American Association of Clinical Endocrinology (AACE) annual meeting being held in San Diego, California from May 12 14, 2022.
  • Key Onsite abstracts presented by Alberto Pedroncelli MD, Head of Clinical Development & Medical Affairs, Global Endocrinology, Recordati AG.
  • For more information visit www.isturisa.com
    About Recordati Rare Diseases Inc.
    Recordati Rare Diseases Inc. is a biopharmaceutical company committed to providing often-overlooked orphan therapies to the underserved rare disease communities of the United States.
  • Recordati Rare Diseases mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies.

Neovasc to Report First Quarter Financial Results on May 12, 2022

Retrieved on: 
Friday, April 29, 2022
Piping and plumbing fitting, International, Intention, TSX, Perception, Risk, GLOBE, Interest, Conference, Forward-looking statement, Company, Private Securities Litigation Reform Act, News, Analysis, EDT, Webcast, NASDAQ, Review, Adrenal insufficiency

VANCOUVER and MINNEAPOLIS, MN, April 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022.

Key Points: 
  • VANCOUVER and MINNEAPOLIS, MN, April 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022.
  • Neovascs President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the companys results at 4:30 pm EDT on May 12, 2022.
  • Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International) and reference Conference ID 13729200.
  • Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at neovasc.com/investors/ .

Neovasc Comments on European Heart Journal Publication

Retrieved on: 
Thursday, April 28, 2022
Piping and plumbing fitting, TSX, Blood, Adrenal insufficiency, Department, Muscle tissue, Patient, Microangiopathy, Male, European Heart Journal, Pain, GLOBE, Union, Angina, History, MD, Cohort study, Heart, European Heart Journal: Cardiovascular Imaging, Physician, NASDAQ, Perfusion, Chest pain, Medical device, Pharmaceutical industry

VANCOUVER and MINNEAPOLIS, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the European Heart Journal has published an article entitled, “Impact of the Coronary Sinus Reducer on Absolute Blood Flow and Microvascular Resistance Case Report.” The article, authored by Francesco Giannini, M.D., Maria Cecilia Hospital, Cotignola, Italy, describes objective improvements in the amount of oxygenated blood delivered to the heart muscle in two patients suffering from refractory angina treated with the Neovasc Reducer™ (“Reducer”).

Key Points: 
  • VANCOUVER and MINNEAPOLIS, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc , Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN) today announced that the European Heart Journal has published an article entitled, Impact of the Coronary Sinus Reducer on Absolute Blood Flow and Microvascular Resistance Case Report.
  • The article, authored by Francesco Giannini, M.D., Maria Cecilia Hospital, Cotignola, Italy, describes objective improvements in the amount of oxygenated blood delivered to the heart muscle in two patients suffering from refractory angina treated with the Neovasc Reducer (Reducer).
  • The second patient was a 78-year-old male suffering from a blocked stented vessel and recurrent chest pain.
  • Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace.

Neovasc Announces Effective Date of Share Consolidation

Retrieved on: 
Wednesday, April 27, 2022
Legislation, Consolidation, Intention, TSX, Perception, Sale, Patient, SEDAR, Nasdaq, Letter, Risk, GLOBE, EDGAR, COVID-19, Indian stock exchange, Shareholder, Forward-looking statement, Growth, Special, Company, Toronto Stock Exchange, CUSIP, Private Securities Litigation Reform Act, Public company, Hospital, Exercise, Marketing, Annual report, News, Physician, ISIN, NASDAQ, Insurance, Industry, Health, Safety, Adrenal insufficiency, Security (finance), Piping and plumbing fitting, BC

The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 68,228,061 Common Shares to approximately 2,729,107 Common Shares.

Key Points: 
  • The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 68,228,061 Common Shares to approximately 2,729,107 Common Shares.
  • The Company's transfer agent, Computershare Investor Services Inc., is anticipated to send a letter of transmittal on April 27, 2022 to the registered holders of Common Shares.
  • The letter of transmittal will contain instructions on how to surrender Common Share certificate(s) representing pre-Consolidation Common Shares to the transfer agent.
  • Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace.

EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody® in Switzerland

Retrieved on: 
Tuesday, April 26, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, MAA, ODD, Prednisone, Sleep, Osteoporosis, Adrenal insufficiency, Marketing, Adult, European Commission, Dexamethasone, Hypogonadism, Hypothyroidism, Adolescence, CAH, Congenital adrenal hyperplasia, Birth, Infertility, Degenerative disease, Death, Patient, Hydrocortisone, Birth defect, Puberty, Suffering, Medication package insert, Mortality, MHRA, Prednisolone, Marketing Authorisation Application, Product, Physician, Union, FDA, Male, Androgen, Risk, Interim, Therapy, Adrenal crisis, Pharmaceutical industry, Diurnal, Swissmedic

EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody as treatment for congenital adrenal hyperplasia (CAH) in Switzerland.

Key Points: 
  • EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody as treatment for congenital adrenal hyperplasia (CAH) in Switzerland.
  • Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Efmody in Switzerland.
  • The MAA submission to Swissmedic for Efmody will be based on the European regulatory dossier and published clinical trial data, with EffRx expecting potential market launch in Switzerland in 2024.
  • We are pleased to deepen our relationship with EffRx to include the distribution and marketing of Efmody in Switzerland.

Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference

Retrieved on: 
Wednesday, April 20, 2022
News, Perception, NASDAQ, Intention, Private Securities Litigation Reform Act, Analysis, GLOBE, Risk, Conference, Company, Forward-looking statement, TSX, Piping and plumbing fitting, Adrenal insufficiency, Pharmaceutical industry

VANCOUVER and MINNEAPOLIS, April 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conference to be held May 2-3, 2022.

Key Points: 
  • VANCOUVER and MINNEAPOLIS, April 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conference to be held May 2-3, 2022.
  • Additionally, a recording of the presentation will be available on the conference website, and will be archived for 90 days.
  • Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace.
  • Forward-looking statements may involve, but are not limited to, the Companys participation at the Bloom Burton & Co. Healthcare Investment Conference and the timing thereof and the growing cardiovascular marketplace.

DGAP-News: Eckert & Ziegler: Radboud University Medical Center Netherlands to Image First Patient with PENTIXAFOR

Retrieved on: 
Tuesday, April 12, 2022
PAN, Nuclear medicine, Primary aldosteronism, TecDAX, Diagnosis, Radiopharmaceutical, III, APA, European Medicines Agency, Lymphoma, RUMC, Multiple myeloma, Aldosterone, Deutsch, Hypertension, Berlin, Prevalence, ISIN, Inflammation, Radboud University Medical Center, Review, Adrenal insufficiency, CXCR4, EMA, PET, BAH, Patient, Phase, AVS, Pharmaceutical industry, Medical imaging, Conn

Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study.

Key Points: 
  • Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study.
  • Developed by PentixaPharm, PENTIXAFOR is an innovative imaging PET tracer that targets the chemokine-4 receptor (CXCR4) and is used to diagnose various oncological and inflammatory diseases.
  • The CASTUS study is a clinical research programme aiming to evaluate the accuracy of PENTIXAFOR in the diagnosis of primary aldosteronism.
  • Eckert & Ziegler (ISIN DE0005659700, TecDAX), the owner of the rights to the underlying [68Ga]Ga-PentixaFor PET compound, is supporting the RUMC team by providing PENTIXAFOR.

egnite, Inc. Announces Data from the Largest Contemporary Analysis of Valvular Heart Disease Prevalence in the United States

Retrieved on: 
Saturday, April 2, 2022
Hospitals, Health, Science, Research, Cardiology, Journal, Adrenal insufficiency, TR, Stenosis, AR, JACC, VHD, Valvular heart disease, Hospital, Intelligence, Prevalence, MR, MS, American College, Data, Male, Solution, Female, Patient, Aortic stenosis, Medical imaging, Cardiology

The data were sourced from the CardioCare platform, which includes a large dataset of echocardiographic reports that can offer insights into contemporary structural heart disease diagnosis and management in real-world practice settings.

Key Points: 
  • The data were sourced from the CardioCare platform, which includes a large dataset of echocardiographic reports that can offer insights into contemporary structural heart disease diagnosis and management in real-world practice settings.
  • Prevalence of VHD continues to be substantial and more common as patients age, with a noticeable increase above 65 years of age.
  • Prevalence of mixed VHD also increased with advancing age; the combination of MR and TR was the most common form of mixed valvular disease.
  • It also suggests a greater prevalence of mitral and tricuspid disease among women with greater prevalence of aortic stenosis among men.